Breast Cancer MSK 19-045

A Safety and Feasibility Study of Limited Cardiac Monitoring during Non-anthracycline Trastuzumab-based Therapy in Patients with HER2-positive Breast Cancer

The purpose of this study is to test whether patients with breast cancer who are being treated with non-anthracycline trastuzumab therapy can safely be monitored for heart related side effects less often than usual.

Eligibility Criteria:

  • Female, Age > 18 years
  • Newly diagnosed histologically confirmed primary invasive breast carcinoma (Stage I-IV)
  • Pathologically confirmed HER2-positive breast cancer
  • Planned to receive trastuzumab-based therapy for a minimum of 12 months, or started trastuzumab-based therapy within the last 6 weeks with a planned duration of at least 12 months
  • Normal LV systolic function (EF greater than or equal to the institutional lower limit of normal) 
  • Have not planned to receive an anthracycline-based regimen
  • No prior history of treatment with anthracycline chemotherapy

This study is for patients age 18 and older.

Available at: Hartford Hospital, Hospital of Central Connecticut, Midstate Medical Center

Cancer Clinical Research Office